title: Treatment of relapsed classical Hodgkin lymphoma in the brentuximab vedotin era.
abstract: Classical Hodgkin lymphoma (HL) relapses after or is refractory to upfront multiagent chemotherapy in 20%-30% of patients. Effective salvage therapy for relapsed or refractory HL is limited, and advancements are needed. Brentuximab vedotin (BV), an anti-CD30 antibody-drug conjugate, has demonstrated significant activity and manageable toxicities in advanced HL. Currently approved as a monotherapy for patients with HL that is relapsed or refractory to multiple lines of chemotherapy or autologous stem cell transplantation, BV is now being evaluated earlier in the course of disease and in combination with other therapies. This review discusses the successful translation of BV from its conception to the clinical setting and highlights ongoing trials that may ultimately expand its role in relapsed or refractory HL and improve outcomes for patients.
authors.affiliation: Department of Medicine and Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA.
authors.forename: Solomon A
authors.initials: SA
authors.lastname: Graf
authors.affiliation: Department of Medicine and Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA.
authors.forename: Ajay K
authors.initials: AK
authors.lastname: Gopal
mesh_terms: D000079963:Brentuximab Vedotin; D004305:Dose-Response Relationship, Drug; D018380:Hematopoietic Stem Cell Transplantation; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D018796:Immunoconjugates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D016879:Salvage Therapy
chemical_list: D018796:Immunoconjugates; D000079963:Brentuximab Vedotin